UMB Dataset
Small molecules inhibitors of the heterogeneous ribonuclear protein A18 (hnRNP A18): a regulator of protein translation and an immune checkpoint
UID: 219
- Description
- Researchers utilized SILCS-based techniques to map the functional group requirements of hnRNP A18, aiming to create a pharmacophore for virtual screening. Data was obtained using the crystal structure of the hnRNP A18 RRM domain and various software tools. These simulations generated 3D functional group probability distributions of organic solutes, forming the basis for pharmacophore models. Virtual screening of compound databases was then conducted using these pharmacophore models. Experimental assays, including PAMPA, NMR spectroscopy, RNA binding activity assays, fluorescence anisotropy, and cellular thermal shift assays, were performed on selected compounds. Finally, in vivo studies on tumor growth inhibition in mice models complemented the in vitro findings.
Access
- Restrictions
-
Unrestricted access
- Instructions
- Datatables available in the Supplementary Materials. Backbone chemical shift assignments for the RRM domain of hnRNP A18 are deposited in the Biological Magnetic Resonance Database.
Interventional
Boltzmann transformation
SILCS-Pharm protocol
four-parameter logistic equation
- Grant Support
-
Cigarette Restitution Fund Program/Maryland. Department of HealthCenter for Biomolecular Therapeutics fund/University of Maryland Computer-Aided Drug Design CenterI.P. Fund/Center for Maryland Advanced Ventures Life Sciences